What are the side effects of Alpelisib-Piqray?

In clinical studies of Alpelisib (Alpelisib)-Piqray, the most common adverse reactions include diarrhea, rash, nausea, fatigue, decreased appetite, stomatitis, vomiting, weight loss, alopecia; laboratory abnormalities It is increased glucose, increased creatinine, decreased lymphocyte count, increased gamma-glutamyl transferase (GGT), increased alanine aminotransferase (ALT), decreased hemoglobin, increased lipase, decreased calcium, decreased glucose, and prolonged activated partial thromboplastin time (aPTT).

Among the warnings and precautions that have emerged in the clinical research of Apellis, severe allergies, severe skin adverse reactions, hyperglycemia, pneumonia, diarrhea or colitis, embryo-fetal toxicity, etc. are more common. Doctors may regularly check the progress of patients using drugs to treat locally advanced or metastatic breast cancer (mBC), and based on the duration and severity of the disease, discontinue, reduce the dose, or permanently stop Apellis. Colitis, hyperglycemic hyperosmolar nonketotic syndrome (HHNKS), angioedema, and drug reactions with eosinophilia and systemic symptoms (DRESS) have also occurred since the marketing of Apelvis.

The original drug of Apellis is not marketed in the country and therefore cannot be included in medical insurance. There are European and Indian versions of the original Apelvis drug sold overseas. The ingredients are basically the same. The price of the European version of 150mg*56 tablets per box may be more than 4 RMB 40,000 ( (The price may fluctuate due to the exchange rate), The price of the Indian version150mg*28 tablets per box may be more than 5,000 yuan (the price may fluctuate due to the exchange rate). There are currently no generic versions of Apelvis produced and marketed.